---
title: Solutions
description: >-
  Explore Pedestal Health RWE solutions for hepatology, dermatology,
  gastroenterology, and more—built to support evidence-ready decisions.
category: Page
canonical_url: https://www.pedestalhealth.com/solutions/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: solutions
id: 39wiyBLtEtZxX5PhcBvJDR
contentType: page
---

# One evidence partner, built for every decision in your clinical program

**Solutions**

Trials begin where the regulatory pathway demands — often without the longitudinal evidence that would inform protocol design, population selection, and feasibility upstream, or the post-approval evidence and access strategy that would be sharpened by understanding how the same patients move through care.

Pedestal Health is built to change both: an integrated evidence partner with the cohorts, technology, and clinical relationships to support your evidence strategy from clinical development to care delivery.

## One model. Evidence across the program.

Pedestal Health's longitudinal cohorts support evidence generation that compounds over time — insights from our longitudinal cohort data shape the trials and prospective studies we run, and what those studies produce flows back into the cohorts as therapies move into care.

Each phase strengthens the next, rather than starting from scratch. The model supports three categories of decisions, each grounded in the same underlying infrastructure.

### R&D Decisions

- Disease characterization, natural history, biomarker work, and feasibility informed by longitudinal cohort data.
- Protocol design and population selection grounded in real clinical contexts.
- Prospective studies and clinical trials run within Pedestal's cohort and site infrastructure.
- External control arms.
- Sub-phenotyping and risk stratification.





- Clinical development
- Translational and Study teams
- Program teams

### Approval & Commercialization Decisions

- Post-authorization safety studies.
- Supplementation of regulatory submissions with longitudinal evidence.
- External control arm contributions to FDA and EMA filings.
- Comparative effectiveness.
- Market access evidence.
- Publication strategy and support.





- Regulatory
- HEOR / Market Access
- Payers
- Medical Affairs

### Care Decisions

- Treatment pattern characterization in routine practice.
- Long-term effectiveness and safety.
- Clinical decision support evidence.
- Therapeutic inertia and treat-to-target gap analyses.
- Partnership infrastructure for clinician-led research and publications.





- Clinicians
- Health systems
- Care delivery teams
- PI-led research


- [Talk to our team](/contact/) 

![Gloved Hand Holding 6-Well Plate with Cell Culture Assay Results (diagonal mask)](https://images.ctfassets.net/h4s3ip99qawo/1BPmrMCWg67SO6WMsucBlq/621975394bcbcd4efd06c248db5e7d16/iStock-1254559622.jpg)

### Hepatology


- [Hepatology](/disease-areas/hepatology/) 

### Dermatology


- [Dermatology](/disease-areas/dermatology/) 

### Gastroenterology


- [Gastroenterology](/disease-areas/gastroenterology/) 

### Future Disease Areas


- [Future Disease Areas](/disease-areas/future/) 

## One system, built for every decision a program faces

Our work has shown us what the field actually needs: not just another retrospective data source or another standalone clinical trial, but a hybrid system that keeps generating evidence on the same patients as the questions evolve. Our approach guides the decisions that matter most to clinical programs in active development as they arise:

### Deep baseline characterization

At enrollment, we capture structured and unstructured EHR data and patients consent to prospective data collection. The starting point is richer than claims or registry data alone, and the same patient stays in the system from there.

### Longitudinal follow-up

The same patients, followed over years. Continuously updated structured and unstructured EHR data alongside the prospectively collected measures from enrollment. The substrate for natural history, disease characterization, treatment patterns, and comparative effectiveness.

### Partner-specific extensions

Programs that need additional PROs, biomarkers, imaging, or other measures can activate them through dedicated protocols layered on the same patient population.

### Clinical trial infrastructure

A network of activated sites and a continuously enrolled patient population already in the system, ready to support embedded prospective studies, external control arms, and trial work that draws on what's already running.

### Post-approval evidence

Patients enrolled before approval and followed past launch on the same continuous infrastructure, with partner-specific protocols providing the rigorous structure required for post-authorization safety, real-world effectiveness, and long-term outcomes work.